EyeCRO specializes in preclinical ophthalmic studies to examine the efficacy of novel test agents and therapeutic modalities. Our models are well established and optimized to facilitate generation of reproducible datasets with meaningful endpoints.
With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals. We also offer Toxicology/PK studies, and eyedrop formulations in MiDROPS™.
The Global Leader in Preclinical Ophthalmic Research
Microemulsion Drug Ocular Penetration System MiDROPS™
MiDROPS™ was developed to allow for eyedrop formulation of small molecules that are lipophilic. This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable. These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment. Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.
Click here to learn more about this innovative platform technology
Models
News & Events
EyeCRO on Twitter
AMD secrets in human subretinal fluid? Molecules between RPE and photoreceptors! Check out transthyretin proteoforms – top-down proteomics, cool surgery video, local TTR expression. Out in Exp Eye Res. https://bit.ly/3bwZLed; @GMalekLab; @choroidlab; @GroupLengyel; @UABophtho;
Regenerative and restorative medicine for eye disease | Nature Medicine https://www.nature.com/articles/s41591-022-01862-8
Landscape of genetic therapies for USH2A-related retinitis pigmentosa https://www.ophthalmologytimes.com/view/landscape-of-genetic-therapies-for-ush2a-related-retinitis-pigmentosa via @OTEurope
Contact Us
EyeCRO – Headquarters
Oklahoma City, OK 73105
EyeCRO – Ann Arbor
Ann Arbor, MI 48104